Agenus Inc - May 3, 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
10%+ Owner
Signature
/s/ Christine Klaskin, Vice President, Finance
Stock symbol
INKT
Transactions as of
May 3, 2023
Transactions value $
$260,189
Form type
4
Date filed
5/5/2023, 06:00 PM
Previous filing
May 26, 2023
Next filing
May 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INKT Common Stock Purchase $139K +129K +0.6% $1.08 21.5M May 3, 2023 Direct F1, F2
transaction INKT Common Stock Purchase $26.2K +21.5K +0.1% $1.22 21.5M May 4, 2023 Direct F2, F3
transaction INKT Common Stock Purchase $94.9K +100K +0.47% $0.95 21.6M May 5, 2023 Direct F4
transaction INKT Common Stock Purchase $250 +200 +0% $1.25 21.6M May 5, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
F2 Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
F3 Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
F4 On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.